Stocktoria
uniQure N.V. QURE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-02-05
uniQure N.V. statistics & valuation
Market cap$3.0B
P / B14.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1151.4% | -679.6% | -1785.5% | -134.4% | 59.3% |
| Net margin | -1236.0% | -883.4% | -1947.1% | — | — |
| FCF margin | -1108.2% | -686.2% | -966.3% | -152.8% | 51.6% |
| Return on assets | -24.1% | -43.0% | -37.1% | — | — |
| Return on equity | -100.0% | 3547.9% | -148.5% | — | — |
| Debt / equity | 0.36× | -9.78× | 0.71× | 0.30× | 0.23× |
| Current ratio | 10.43 | 9.74 | 8.85 | 6.28 | 17.09 |
| Revenue growth | -40.6% | 71.2% | -85.1% | -79.7% | 1296.8% |
Source: SEC EDGAR filings · CIK 0001590560 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.